|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/18 | (2006.01) |
| C07K 16/40 | (2006.01) | ||
| A61P 29/00 | (2006.01) | ||
| A61P 37/06 | (2006.01) |
| (11) | Number of the document | 2970455 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15710396.1 |
| Date of filing the European patent application | 2015-03-06 | |
| (97) | Date of publication of the European application | 2016-01-20 |
| (45) | Date of publication and mention of the grant of the patent | 2016-08-17 |
| (46) | Date of publication of the claims translation | 2016-10-25 |
| (86) | Number | PCT/US2015/019225 |
| Date | 2015-03-06 |
| (87) | Number | WO 2015/134894 |
| Date | 2015-09-11 |
| (30) | Number | Date | Country code |
| 201461949932 P | 2014-03-07 | US |
| (72) |
ANDRIEN, Bruce, A., Jr., US
SHERIDAN, Douglas, L., US
TAMBURINI, Paul, P., US
WANG, Yi, US
|
| (73) |
Alexion Pharmaceuticals, Inc.,
352 Knotter Drive, Cheshire, CT 06410,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Anti-C5 antikūnai, turintys pagerintą farmakokinetiką |
| ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS |
| Payment date | Validity (years) | Amount | |
| 2025-02-18 | 11 | 289.00 EUR |
| 2026-03-06 |